Approved Drugs for Pulmonary/Respiratory Diseases
Adcirca (tadalafil); Eli Lilly;
For the treatment of pulmonary arterial hypertension, Approved May 2009
Tyvaso (treprostinil); United Therapeutics;
For the treatment of pulmonary arterial hypertension, Approved July 2009
Alvesco (ciclesonide); Nycomed;
For the maintenance treatment of asthma as prophylactic therapy in adults and adolescents, Approved January 2008
Patanase (olopatadine hydrochloride); Alcon;
For the treatment of seasonal allergic rhinitis, Approved April 2008
Letairis (ambrisentan); Gilead;
For the treatment of pulmonary arterial hypertension, Approved June 2007
Xyzal (levocetirizine dihydrochloride); UCB;
For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007
Brovana (arformoterol tartrate); Sepracor;
For the treatment of Chronic Obstructive Pulmonary Disease, Approved in October 2006
Tygacil (tigecycline); Wyeth;
For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005
Ketek (telithromycin); Sanofi-aventis;
For the treatment of infections caused by bronchitis, bacterial sinusitis and Community-acquired pneumonia., Approved April 2004
Spiriva HandiHaler (tiotropium bromide); Boehringer Ingelheim;
For the treatment of bronchospasm associated with chronic obstructive pulmonary disease, Approved February 2004
Aldurazyme (laronidase); Genzyme;
For the treatment of Mucopolysaccharidosis I (MPS I) in subjects aged 5 to 65, Approved May 2003
Iressa (gefitinib); AstraZeneca;
For the second-line treatment of non-small-cell lung cancer, Approved May 2003
Xolair (omalizumab); Genentech;
For the treatment of asthma, Approved June 2003
Zemaira (alpha1-proteinase inhibitor); Aventis Behring;
For the treatment of alpha1-proteinase inhibitor deficiency (Alpha-1) and emphysema, Approved July 2003
Clarinex; Schering-Plough;
Once-daily oral tablet for the treatment of allergic rhinitis and chronic ideopathic urticaria, Approved February 2002
Qvar (beclomethasone dipropionate); Ivax;
For the treatment of asthma, Approved May 2002
Remodulin (treprostinil); United Therapeutics;
For the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms, Approved May 2002
Xopenex; Sepracor;
Inhaled solution for treatment of reversible obstructive airway disease, Approved February 2002
Avelox I.V. (moxifloxacin hydrochloride); Bayer;
Injectable antibacterial agent for adults with susceptible strains of bacterial infections, Approved November 2001
DuoNeb (albuterol sulfate and ipratropium bromide); Dey Laboratories;
For the treatment of bronchospasm associated with COPD, Approved March 2001
Foradil Aerolizer (formoterol fumarate inhalation powder); Novartis;
Bronchodilator for COPD, asthma and bronchospasm, Approved February 2001 (asthma, bronchospasm); September 2001 (COPD)
Invanz; Merck;
Once-daily injectable treatment for bacterial infections, Approved November 2001
NasalCrom Nasal Spray; Pharmacia;
Over-the-counter nasal spray for treatment of all nasal allergy symptoms, Approved April 2001
Tavist (clemastine fumarate); Novartis;
Oral tablet for temporary relief of symptoms associated with hay fever, allergic rhinitis, and the common cold, Approved March 2001
Tracleer (bosentan); Actelion;
For the treatment of pulmonary arterial hypertension, Approved November 2001
Ventolin HFA (albuterol sulfate inhalation aerosol); GlaxoSmithKline;
For the treatment or prevention of bronchospasm, Approved April 2001
Biaxin XL (clarithromycin extended-release tablets); Abbott Laboratories;
For Acute Bacterial Exacerbation of Chronic Bronchitis (AECB) and Acute Maxillary Sinusitis, Approved March 2000
Cefazolin and Dextrose USP; B Braun Medical;
Respiratory tract infections, Approved July 2000
Tri-Nasal Spray (triamcinolone acetonide spray); Muro Pharmaceutical;
For treatment of nasal symptoms of allergic rhinitis in adults and children age 12 or older, Approved February 2000
Accolate; AstraZeneca;
zafirlukast, 10 mg and 20 mg tablets., Approved September 1999
Cafcit Injection; Roxane Laboratories;
For the short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age., Approved September 1999
Proventil HFA Inhalation Aerosol; 3M Pharmaceuticals;
Treatment or prevention of bronchospasm, Approved June 1999
Rhinocort Aqua Nasal Spray; AstraZeneca;
A nasal spray containing budesonide, Approved October 1999
Tequin; Bristol-Myers Squibb;
Tequin (Injectable and Tablet), December, 1999
Tikosyn Capsules; Pfizer;
Capsules of dofetilide, Approved October 1999
Allegra-D; Hoechst Marion Roussel;
Treatment for nasal congestion due to seasonal allergy, Approved March 1998
Clemastine fumarate syrup; Morton Grove Pharmaceuticals;
Generic equivalent of Tavist Syrup, Approved March 1998
Curosurf; Dey Laboratories;
Treatment for respiratory distress syndrome in premature infants., Approved October 1998
Dynabac; Sanofi-aventis;
Treatment for acute bacterial exacerbations (chronic bronchitis and skin infections), Approved March 1998
Infasurf; ONY;
For the prevention and treatment of Respiratory Distress Syndrome (RDS) in premature infants, Approved July 1998.
Priftin; Hoechst Marion Roussel;
Treatment for pulmonary tuberculosis, Approved June 1998
Pulmozyme (dornase alfa); Genentech;
Treatment for cystic fibrosis, Approved March 1998
Sclerosol Intrapleural Aerosol; Bryan Corporation;
Treatment for malignant pleural effusions, Approved January 1998
Singulair; Merck;
Treatment for asthma, Approved February 1998
Synagis; MedImmune;
Treatment for the prevention of serious lower respiratory tract disease in infants, Approved June 1998
Ceftin (cefuroxime axetil); GlaxoSmithKline;
Treatment of secondary bacterial infections of acute bronchitis, Approved September 1997
Cipro (ciprofloxacin HCl); Bayer;
Treatment for acute sinusitis, Approved June 1997
Claritin RediTabs (10 mg loratadine rapidly-disintegrating tablet); Schering-Plough;
Treatment for seasonal allergy symptoms, Approved January 1997
Flonase Nasal Spray; GlaxoSmithKline;
Treatment for seasonal and perennial allergic rhinitis, Approved November 1997
Flovent Rotadisk; GlaxoSmithKline;
Treatment of asthma in patients four and older, Approved November 1997
Metaprotereol Sulfate Inhalation Solution, 5%; Morton Grove Pharmaceuticals;
Generic equivalent of Alupentr Inhalation Solution, 5%, Approved March 1997
Nasacort AQ (triamcinolone acetonide) Nasal Spray; Phone-Poulenc Rorer;
Treatment of nasal symptoms of seasonal allergic rhinitis in children Aged 6-11, Approved October 1997
Omnicef; Warner-Lambert;
Treatment against various bacterias, Approved December 1997
Raxar (grepafloxacin); GlaxoSmithKline;
Treatment for chronic bronchitis, Approved November 1997
Serevent; GlaxoSmithKline;
Treatment of asthma, Approved September 1997
Tilade (nedocromil sodium); Rhone Poulenc Rorer;
Treatment for mild-to-moderate bronchial asthma, Approved April 1997
Tilade (nedocromil sodium); Rhone Poulenc Rorer;
Treatment for asthma, Approved April 1997
Tilade (nedocromil sodium); Rhone Poulenc Rorer;
Treatment for mild to moderate asthma, Approved November 1997
Tobi; PathoGenesis;
Treatment for cystic fibrosis, Approved December 1997
Vanceril 84 mcg Double Strength (beclomethasone dipropionate, 84 mcg) Inhalation Aerosol; Schering-Plough;
Treatment for asthma, Approved January 1997
Zagam (sparfloxacin) tablets; Rhone Poulenc Rorer;
Treatment for community-acquired pneumonia (CAP) and chronic bronchitis, Approved January 1997
Zyflo (Zileuton); Abbott Laboratories;
Treatment for asthma in patients 12 years and older, Approved January 1997
Accolate; AstraZeneca;
Treatment for asthma, Approved October 1996
Allegra (fexofenadine hydrochloride); Hoechst Marion Roussel;
Treatment for seasonal allergy symptoms, Approved July 1996
Astelin nasal spray; Wallace Laboratories;
Treatment for seasonal allergic rhinitis, Approved November 1996
Atrovent (ipratropium bromide); Boehringer Ingelheim;
Treatment for runny nose due to allergies and the common cold, Approved January 1996
Augmentin (amoxicillin/clavulanate); SmithKline Beecham;
Treatment for infections involving drug-resistant bacteria, Approved February 1996
Azmacort (triamcinolone acetonide) Inhalation Aerosol; Rhone Poulenc Rorer;
Treatment for asthma, Approved November 1996
Breathe Right; CNS;
Treatment for breathing difficulties due to deviated nasal septum, Approved June 1996
Claritin Syrup (loratadine); Schering-Plough;
Treatment for children with seasonal allergies, Approved October 1996
Claritin-D 24 Hour Extended Release Tablets (10 mg loratadine, 240 mg pseudoephedrine sulfate); Schering-Plough;
Treatment for nasal congestion, Approved August 1996
Covera-HS (verapamil); G.D. Searle, Alza;
Treatment for hypertension and angina, Approved January 1996
Nasacort AQ (triamcinolone acetonide) Nasal Spray; Rhone Poulenc Rorer;
Treatment for allergic rhinitis, Approved May 1996
OcuHist; Pfizer;
Over-the-counter antihistamine eye drop, Approved January 1996
Pulmozyme (dornase alfa); Genentech;
Treatment for cystic fibrosis patients with advanced disease, Approved December 1996
RespiGam (Respiratory Syncitial Virus Immune Globulin Intravenous); MedImmune;
Treatment for the prevention of respiratory syncytial virus disease, Approved January 1996
Tavist (clemastine fumarate); Sandoz Pharmaceuticals;
Treatment for cold symptoms, Approved November 1996
Tripedia (Diptheria and Tetanus Toxoids and Acellular Pertussis Vaccine Absorbed); Connaught Laboratories;
Treatment for whooping cough, Approved August 1996
Vancenase AQ 84 mcg Double Strength; Schering-Plough;
Treatment for allergic and non-allergic rhinitis, Approved June 1996
Visipaque (iodixanol); Nycomed;
Diagnostic contrast agent, Approved April 1996
Zosyn (sterile piperacillin sodium/tazobactam sodium); Wyeth;
Treatment for hospital-acquired pneumonia, Approved May 1996
Cedax (ceftibuten); Schering-Plough;
Treatment for chronic bronchitis, acute bacterial otitis media, pharyngitis/tonsillitis, Approved December 1995
Zyrtec (cetirizine HCl); Pfizer;
Treatment for year-round allergies, seasonal allergic rhinitis, and chronic itching and hives, Approved December 1995
